Ozdemir O, Boran M, Gökçe V, Uzun Y, Koçak B, Korkmaz S
Department of Cardiology, Türkiye Yüksek Ihtisas Hastanesi, Ankara, Turkey.
Angiology. 2000 Aug;51(8):695-7.
Gemfibrozil-statin combination therapy is a well-known risk factor for myopathy and rhabdomyolysis. Cerivastatin is a currently available statin with dual elimination; it is therefore expected to cause less drug-drug interaction. This case is the second reported case with severe rhabdomyolysis caused by cerivastatin-gemfibrozil combination. Moreover, in this case, the rhabdomyolysis was more severe and caused severe renal failure and death. The authors discuss how these drugs cause rhabdomyolysis and how rhabdomyolysis can cause renal failure.
吉非贝齐-他汀联合治疗是众所周知的导致肌病和横纹肌溶解的危险因素。西立伐他汀是一种目前可用的具有双重消除作用的他汀类药物；因此预计它会引起较少的药物相互作用。该病例是第二例报道的由西立伐他汀-吉非贝齐联合用药导致严重横纹肌溶解的病例。此外，在该病例中，横纹肌溶解更为严重，并导致了严重肾衰竭和死亡。作者讨论了这些药物如何引起横纹肌溶解以及横纹肌溶解如何导致肾衰竭。
